Q-omics provides the consensus-scored MIR210 profile across patient tissues and cancer cell-line models. MIR210 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR210 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MIR210 RNA expression shows 14,215 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, KIRC, and UVM as cancer lineages where MIR210 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR210 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR210 survival associations across molecular data types. MIR210 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR210 RNA expression–survival associations across cancer types. High MIR210 expression shows unfavorable associations in CESC, KICH, COAD, ACC, PRAD and UVM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR210 RNA expression.
This table summarizes MIR210 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR210. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR210 shows lower tumor expression in LUAD and higher tumor expression in KIRC, LUSC, COAD, PAAD and CHOL. The KIRC box plot shows higher MIR210 RNA expression in tumor versus normal tissue (log2 FC = +2.038, t-test p < 0.001).
This table shows molecular features associated with MIR210 in patient tissues and cancer cell lines. In patient samples, MIR210 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
